Please login to the form below

Not currently logged in
Email:
Password:

J&J’s clinical research neuroscience director joins MedAvante

Dr Michael Ropacki becomes head of R&D at the clinical data service

MedAvante Dr Michael RopackiGlobal clinical data services company MedAvante has appointed Dr Michael Ropacki as vice president of research and development.

Dr Ropacki joins MedAvante from Johnson & Johnson, where he served as clinical research neuroscience director in its Janssen research and development arm.

Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013.

He also brings experience as associate director and principal clinical scientist at Johnson & Johnson's biotech Centocor, which he first joined as a clinical scientist in 2004.

Paul Gilbert, MedAvante's chief executive officer, said: “Michael Ropacki is widely recognised for the groundbreaking trial methodology he has implemented for registries and prospective cohort studies.

“He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition to MedAvante's scientific leadership team.”

24th February 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics